Prognosis Biotech

Prognosis Biotech company information, Employees & Contact Information

At ProGnosis Biotech, we're not just advancing diagnostics, we're shaping a sustainable and safer tomorrow. Headquartered in Larissa, Greece, with a strong presence through subsidiaries in 10 countries, we are a globally recognized, export-driven enterprise. Utilizing state-of-the-art ELISA and Lateral Flow technologies, we deliver unmatched precision and reliability in food safety, clinical, and veterinary diagnostics. By integrating real-time data sharing through mobile applications with GPS connectivity, we empower stakeholders to make informed decisions instantly, enhancing transparency and safety across the entire supply chain. Since 2011, our commitment to innovative and eco-friendly solutions has empowered industries and protected lives in over 80 countries worldwide. What Sets Us Apart? 🌍 Global Recognition by Renowned Institutions: ILVO, AOAC, USDA, LILC, PIWET, ensuring the highest quality and reliability of our products. 🔬 Innovative Technology: From proprietary antibodies to cloud-connected mobile apps, we revolutionize diagnostics with real-time data sharing and GPS-enabled insights, boosting transparency and efficiency. 📋 Total Quality Commitment: Guided by ISO 9001, ISO 13485, and ISO 37001 certifications, we uphold the strictest quality standards across all processes. 🤝 Dedicated Customer Support: Our diagnostic tools come with hands-on training and continuous support, ensuring seamless integration into your operations. 🛠️ Custom Business Solutions: We collaborate to develop precise diagnostics that fit your specific needs. 🌱 Sustainability in Focus: Designing diagnostic tools that not only perform exceptionally but also minimize environmental impact. ProGnosis Biotech: Accuracy through innovation Building trust across the supply chain together – from field to shelf. 🌿
Looking for a particular Prognosis Biotech employee's phone or email?

Prognosis Biotech Questions

News

Sellas’ CDK9 inhibitor tied to 50% response rate in certain AML patients in phase 2 study - Fierce Biotech

Sellas’ CDK9 inhibitor tied to 50% response rate in certain AML patients in phase 2 study Fierce Biotech

Mycotoxin Testing Market Size, Share | CAGR of 7.3% - Market.us

Mycotoxin Testing Market Size, Share | CAGR of 7.3% Market.us

Boehringer inks Tessellate deal to slot synthetic lethal program into oncology pipeline - Fierce Biotech

Boehringer inks Tessellate deal to slot synthetic lethal program into oncology pipeline Fierce Biotech

5 new products at Dairy-Tech 2025 to improve efficiency - Farmers Weekly

5 new products at Dairy-Tech 2025 to improve efficiency Farmers Weekly

ASCO: OSE shares 65% overall survival rate behind therapeutic cancer vaccine's phase 2 win - Fierce Biotech

ASCO: OSE shares 65% overall survival rate behind therapeutic cancer vaccine's phase 2 win Fierce Biotech

'Unbelievably blessed': First custom CRISPR therapy alleviates worst of rare genetic disease for infant - Fierce Biotech

'Unbelievably blessed': First custom CRISPR therapy alleviates worst of rare genetic disease for infant Fierce Biotech

US biotechs think twice about EU licensing deals amid Trump's drug pricing campaign - Fierce Biotech

US biotechs think twice about EU licensing deals amid Trump's drug pricing campaign Fierce Biotech

Introducing Fierce Biotech's 2023 Fierce 15 - Fierce Biotech

Introducing Fierce Biotech's 2023 Fierce 15 Fierce Biotech

Following in Biogen's wake, BrainStorm analyzes effect of ALS cell therapy on biomarker - Fierce Biotech

Following in Biogen's wake, BrainStorm analyzes effect of ALS cell therapy on biomarker Fierce Biotech

ASCO: Early Purple data gain ground in metastatic pancreatic cancer - Fierce Biotech

ASCO: Early Purple data gain ground in metastatic pancreatic cancer Fierce Biotech

CDx Biomarkers for Oncology Research & Development - Fierce Biotech

CDx Biomarkers for Oncology Research & Development Fierce Biotech

Amgen's FGFR2b-targeting cancer candidate boosts overall survival in phase 3 - Fierce Biotech

Amgen's FGFR2b-targeting cancer candidate boosts overall survival in phase 3 Fierce Biotech

Fierce Medtech's 2020 Fierce 15 - Fierce Biotech

Fierce Medtech's 2020 Fierce 15 Fierce Biotech

Revealing new insights from the Tumor Microenvironment with AI-powered digital pathology - Fierce Biotech

Revealing new insights from the Tumor Microenvironment with AI-powered digital pathology Fierce Biotech

Health Logic Interactive is developing an Innovative POC Digital Device for CKD - Fierce Biotech

Health Logic Interactive is developing an Innovative POC Digital Device for CKD Fierce Biotech

Adaptimmune gears up for another FDA submission after hitting goal in pivotal sarcoma study - Fierce Biotech

Adaptimmune gears up for another FDA submission after hitting goal in pivotal sarcoma study Fierce Biotech

'Our data is resonating far more with the people that matter,' Bicara CEO says amid Merus race - Fierce Biotech

'Our data is resonating far more with the people that matter,' Bicara CEO says amid Merus race Fierce Biotech

AACR: Cancer vaccines get a reintroduction as readouts support 'path forward' for the tech - Fierce Biotech

AACR: Cancer vaccines get a reintroduction as readouts support 'path forward' for the tech Fierce Biotech

AstraZeneca’s AL amyloidosis drug fails to reduce mortality in phase 3 test - Fierce Biotech

AstraZeneca’s AL amyloidosis drug fails to reduce mortality in phase 3 test Fierce Biotech

Novartis' $2.9B MorphoSys bet stumbles as safety signal delays filing by years - Fierce Biotech

Novartis' $2.9B MorphoSys bet stumbles as safety signal delays filing by years Fierce Biotech

Blood testing nears a turning point as the evidence becomes undeniable - Fierce Biotech

Blood testing nears a turning point as the evidence becomes undeniable Fierce Biotech

Public-private collaboration aims to take ALS therapies beyond 'a shot in the dark' - Fierce Biotech

Public-private collaboration aims to take ALS therapies beyond 'a shot in the dark' Fierce Biotech

Novo Nordisk inks $1B Cardior buyout to pump up heart failure plans - Fierce Biotech

Novo Nordisk inks $1B Cardior buyout to pump up heart failure plans Fierce Biotech

ASCO: Jazz shares 'unprecedented' HER2 biliary tract cancer data ahead of FDA decision - Fierce Biotech

ASCO: Jazz shares 'unprecedented' HER2 biliary tract cancer data ahead of FDA decision Fierce Biotech

AACR: Boehringer Ingelheim proves durability of 'unparalleled' HER2-mutant lung cancer candidate - Fierce Biotech

AACR: Boehringer Ingelheim proves durability of 'unparalleled' HER2-mutant lung cancer candidate Fierce Biotech

Boundless Bio corrals $105M financing round to prep aggressive cancer programs for clinic - Fierce Biotech

Boundless Bio corrals $105M financing round to prep aggressive cancer programs for clinic Fierce Biotech

ESMO: Daiichi unveils first early peek at next-gen ADC as analysts see strong data against rivals - Fierce Biotech

ESMO: Daiichi unveils first early peek at next-gen ADC as analysts see strong data against rivals Fierce Biotech

The top 15 biopharma licensing deals of 2020 - Fierce Biotech

The top 15 biopharma licensing deals of 2020 Fierce Biotech

The 10 highest value R&D projects in biopharma - Fierce Biotech

The 10 highest value R&D projects in biopharma Fierce Biotech

Cell therapy reckoning: How a 'remarkable resolution of lupus' carried CAR-T from cancer to immunology - Fierce Biotech

Cell therapy reckoning: How a 'remarkable resolution of lupus' carried CAR-T from cancer to immunology Fierce Biotech

ASCO: Amgen deals 'knockdown punch' with Lumakras approval, but decades of work lie ahead - Fierce Biotech

ASCO: Amgen deals 'knockdown punch' with Lumakras approval, but decades of work lie ahead Fierce Biotech

Galecto cans lung fibrosis work after phase 2 fail, with all eyes now on liver cirrhosis med - Fierce Biotech

Galecto cans lung fibrosis work after phase 2 fail, with all eyes now on liver cirrhosis med Fierce Biotech

In 2 papers, researchers piece together how micronuclei in cancer cells collapse and contribute to disease progression - Fierce Biotech

In 2 papers, researchers piece together how micronuclei in cancer cells collapse and contribute to disease progression Fierce Biotech

ASCO: Johnson & Johnson's anti-BCMA CAR-T, improving with time, sweeps multiple myeloma aside - Fierce Biotech

ASCO: Johnson & Johnson's anti-BCMA CAR-T, improving with time, sweeps multiple myeloma aside Fierce Biotech

Owkin's mesothelioma AI discovers new biomarkers from lung biopsy images - Fierce Biotech

Owkin's mesothelioma AI discovers new biomarkers from lung biopsy images Fierce Biotech

ASCO: Novartis backs up $2.1B Endocyte buyout with prostate cancer data - Fierce Biotech

ASCO: Novartis backs up $2.1B Endocyte buyout with prostate cancer data Fierce Biotech

ASCO: Novartis' Tafinlar-Mekinist combo gets a boost from PD-1 immunotherapy - Fierce Biotech

ASCO: Novartis' Tafinlar-Mekinist combo gets a boost from PD-1 immunotherapy Fierce Biotech

AASLD: Gilead wants to move the needle for fatty liver therapies - Fierce Biotech

AASLD: Gilead wants to move the needle for fatty liver therapies Fierce Biotech

Bicycle raises £40M to take cancer drugs into the clinic - Fierce Biotech

Bicycle raises £40M to take cancer drugs into the clinic Fierce Biotech

Another one BiTEs the dust as Amgen pauses enrollment for phase 1 bispecific trial - Fierce Biotech

Another one BiTEs the dust as Amgen pauses enrollment for phase 1 bispecific trial Fierce Biotech

Walden Biosciences launches with $51M and a 2-pronged approach to 'completely transform' kidney disease - Fierce Biotech

Walden Biosciences launches with $51M and a 2-pronged approach to 'completely transform' kidney disease Fierce Biotech

How ROS loss leads to inflammatory bowel disease - Fierce Biotech

How ROS loss leads to inflammatory bowel disease Fierce Biotech

AACR: After blood cancer successes, CAR-T treatments see inroads for solid cancers - Fierce Biotech

AACR: After blood cancer successes, CAR-T treatments see inroads for solid cancers Fierce Biotech

Targeted drug combo attacks breast cancer brain metastases in mice - Fierce Biotech

Targeted drug combo attacks breast cancer brain metastases in mice Fierce Biotech

New strategies for improving pancreatic cancer treatments - Fierce Biotech

New strategies for improving pancreatic cancer treatments Fierce Biotech

Seattle Genetics stops all trials of '33A blood cancer drug after patient deaths - Fierce Biotech

Seattle Genetics stops all trials of '33A blood cancer drug after patient deaths Fierce Biotech

News of Note—The bad genes behind cancer; How T cells drive autoimmune diseases - Fierce Biotech

News of Note—The bad genes behind cancer; How T cells drive autoimmune diseases Fierce Biotech

Top Prognosis Biotech Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant